Emergent BioSolutions

Emergent BioSolutions Newswire

Comprehensive Real-Time News Feed for Emergent BioSolutions.

Results 1 - 20 of 62 in Emergent BioSolutions

  1. Bernero: Crowdfunding Plan To Pay For Downtown Soccer FieldRead the original story w/Photo

    Thursday Apr 16 | WLNS-TV Lansing

    ... will have one month to reach the $60,000 crowdfunding goal. There is already corporate support with Emergent Biosolutions donating $10,000 and Jackson National Life committing to give $20,000 to the fundraising effort. The idea for Beacon Field is ...

    Comment?

  2. GlaxoSmithKline establishing vaccine research center in Rockville, bringing 600 jobsRead the original story w/Photo

    Thursday Apr 2 | The Baltimore Sun

    British drug maker GlaxoSmithKline is establishing a vaccine research center in Rockville that it expects will bring 600 jobs to the state. At its growing East Baltimore facility, Emergent BioSolutions has produced a booster shot to go with a leading Ebola vaccine candidate, joining a competitive race to make a safe and effective tool to stop the spread of an outbreak that continues in West Africa and to prevent future outbreaks.

    Comment?

  3. Emergent BioSolutions Receives FDA Approval for AnthrasilRead the original story w/Photo

    Wednesday Mar 25 | Pharmaceutical Processing

    Emergent BioSolutions has announced that the U.S. Food and Drug Administration has approved Anthrasila [Anthrax Immune Globulin Intravenous ], also known as AIGIV, for treatment of inhalational anthrax in combination with appropriate antibacterial drugs. Achievement of this milestone triggers a $7 million payment to the company under a development contract with the Biomedical Advanced Research and Development Authority .

    Comment?

  4. Emergent gets $31M contract for next-generation anthrax vaccineRead the original story w/Photo

    Tuesday Mar 24 | Business Journal

    Rockville-based Emergent BioSolutions, whose anthrax vaccine BioThrax is driving revenue growth, will move toward final clinical trials for its next generation anthrax vaccine with a $31 million BARDA contract. Rockville-based Emergent BioSolutions Inc. is adding a $31 million contract from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to its ongoing work developing a next-generation anthrax vaccine.

    Comment?

  5. Emergent BioSolutions Awarded $31 Million Contract For Advanced...Read the original story

    Monday Mar 23 | BioSpace

    Emergent BioSolutions Inc. announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority for the advanced development of NuThraxTM , also known as AV7909, the company's next generation anthrax vaccine candidate. The contract, valued at $31 million, consists of a 30-month base period of performance to develop NuThrax for post-exposure prophylaxis of anthrax disease.

    Comment?

  6. Baltimore biotech Asklepion lands FDA approval of drug to treat rare digestive illnessRead the original story w/Photo

    Mar 18, 2015 | The Baltimore Sun

    The Food and Drug Administration on Tuesday approved Cholbam, developed by Baltimore biotechnology company Asklepion Pharmaceuticals, for treatment of a rare disease that prevents people from making key digestive acids. At its growing East Baltimore facility, Emergent BioSolutions has produced a booster shot to go with a leading Ebola vaccine candidate, joining a competitive race to make a safe and effective tool to stop the spread of an outbreak that continues in West Africa and to prevent future outbreaks.

    Comment?

  7. Emergent BioSolutions produces new Ebola vaccine teaming with NIH GlaxoSmithKlineRead the original story

    Mar 17, 2015 | Big News Network.com

    Our eNewspaper network was founded in 2002 to provide stand-alone digital news sites tailored for the most searched-for locations for news. With a traditional newspaper format, more than 100 sites were established each with a newspaper-type name to cover the highest-ranked regions, countries, cities and states.

    Comment?

  8. Emergent BioSolutions produces new Ebola vaccine, teaming with NIH, GlaxoSmithKlineRead the original story w/Photo

    Mar 16, 2015 | The Baltimore Sun

    ... Clinic in Monrovia, Liberia. (Jerome Delay, Associated Press) At its growing East Baltimore facility, Emergent BioSolutions has produced a booster shot to go with a leading Ebola vaccine candidate, joining in a competitive race to make a safe and ...

    Comment?

  9. Emergent BioSolutions manufactures possible Ebola vaccine for clinical trials with GlaxoSmithKlineRead the original story w/Photo

    Mar 16, 2015 | Business Journal

    Gaithersburg's Emergent BioSolutions Inc. manufactured an Ebola vaccine candidate that will be tested as a potential booster for the GlaxoSmithKline frontrunner in the race to create an effective Ebola vaccine, officials said Monday. Gaithersburg-based Emergent produced a vaccine batch that will be used by Oxford University researchers in a Phase 1 clinical trial with GlaxoSmithKline's Ebola candidate.

    Comment?

  10. Ebola booster vaccine trial to combine GSK, Emergent Bio shotsRead the original story

    Mar 16, 2015 | Reuters

    Scientists are to test a new two-shot Ebola vaccine using an experimental shot from Britain's GlaxoSmithKline, which is already in clinical trials in Africa, and a new kind of booster from Emergent BioSolutions . The Maryland-based biotech company said on Monday its modified vaccinia Ankara Ebola Zaire vaccine would be used in an initial Phase I clinical study to be conducted by researchers at the University of Oxford.

    Comment?

  11. Emergent Inks Ebola Vax ContractsRead the original story w/Photo

    Mar 16, 2015 | Contract Pharma Breaking News

    Emergent BioSolutions, Inc. has signed several agreements with the University of Oxford , GSK , and the National Institutes of Health's National Institute of Allergy and Infectious Diseases respectively, for the manufacture of a modified vaccinia Ankara Ebola Zaire vaccine candidate for use in a Phase I trial. The study will evaluate the safety of MVA EBOZ as a heterologous boost to GSK's Chimp Adenovirus type 3 Ebola vaccine candidate.

    Comment?

  12. Emergent BioSolutions Signs Agreements With Oxford University,...Read the original story

    Mar 15, 2015 | BioSpace

    Emergent BioSolutions Inc. today announced that, under several agreements signed with the University of Oxford, GSK, and the National Institutes of Health's National Institute of Allergy and Infectious Diseases respectively, it has manufactured a modified vaccinia Ankara Ebola Zaire vaccine candidate anticipated for use in a Phase 1 clinical study to be conducted by Professor Adrian Hill of the Jenner Institute. This clinical trial is being supported by a grant from the Wellcome Trust and the UK Department for International Development.

    Comment?

  13. Profits up at Emergent BioSolutionsRead the original story

    Mar 11, 2015 | Gazette.net

    Emergent BioSolutions of Gaithersburg, which develops biodefense products, including anthrax vaccines, reported that its profit last year grew to $36.7 million from $30.3 million in 2013. Revenues rose to $450.1 million from $312.7 million.

    Comment?

  14. MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study...Read the original story

    Mar 8, 2015 | PR-inside.com

    MorphoSys AG / MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer . Processed and transmitted by NASDAQ OMX Corporate Solutions.

    Comment?

  15. Emergent BioSolutions And MorphoSys AG Initiate Phase 1 Clinical...Read the original story

    Mar 8, 2015 | BioSpace

    Emergent BioSolutions And MorphoSys AG Initiate Phase 1 Clinical Study To Evaluate The Novel Oncology Immunotherapeutic MOR209/ES414 For Prostate Cancer GAITHERSBURG, Md. and MARTINSRIED/MUNICH, Germany, March 9, 2015 -- Emergent BioSolutions Inc. and MorphoSys AG today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer .

    Comment?

  16. MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study...Read the original story

    Mar 8, 2015 | GlobeNewswire

    MorphoSys AG and Emergent BioSolutions Inc. today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer . Under the terms of the companies' co-development and commercialization agreement, the achievement of this milestone triggers a payment of US $ 5 million by MorphoSys to Emergent.

    Comment?

  17. Emergent Biosolutions Inc's Unexpected SurpriseRead the original story

    Mar 5, 2015 | The Motley Fool

    For the most part, the numbers released Thursday fell within the ranges previously announced. Technically, the revenue was slightly higher than Emergent BioSolutions had estimated -- $450.1 million versus an estimate of $445 to $450 million -- but what's $100,000 among friends? All told, it was a pretty good year for Emergent BioSolutions.

    Comment?

  18. Emergent Biosolutions (EBS) Set to Announce Quarterly Earnings on ThursdayRead the original story

    Mar 3, 2015 | AmericanBankingNews.com

    Emergent Biosolutions will issue its quarterly earnings data on Thursday, March 5th. Parties interested in participating in the company's conference call can do so using this link .

    Comment?

  19. Emergent BioSolutions to Participate in March 2015 Investor ConferencesRead the original story

    Feb 20, 2015 | Digital Post Production

    GAITHERSBURG, Md., Feb. 20, 2015 -- Emergent BioSolutions Inc. announced today that a member of the company's senior management team will participate in the following investor conferences in March 2015: For the Cowen and Company conference, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under " Investors ."

    Comment?

  20. Emergent BioSolutions Announces Primary Endpoints Met In Pivotal...Read the original story

    Feb 12, 2015 | BioSpace

    Emergent BioSolutions Inc. today announced completion of the in-life phase of the pivotal nonclinical efficacy study designed to demonstrate that BioThraxA manufactured at large scale in the company's new modern facility, Building 55, is comparable to the BioThrax currently manufactured in its approved facility, Building 12. Interim analysis has shown that the primary endpoints were met; these include demonstrating comparability to vaccine manufactured in Building 12 as well as consistency between lots manufactured in Building 55. Data from this study will be used to support a supplemental Biologics License Application to the U.S. Food and Drug Administration for licensure of Building 55. BioThrax is the only FDA-licensed vaccine for the prevention of anthrax disease.

    Comment?